The overproduction of ROS activates the ATR-Chk1 axis, resulting in resistance to cisplatin in ovarian cancer cells, and the inhibition of ATR and Chk1 reverses chemotherapeutic resistance 145. Here, CHEK1 is linked to ovarian cancer.